Balixafortide TFA (Synonyms: POL6326 TFA) |
| Katalog-Nr.GC39343 |
Balixafortide TFA (POL6326 TFA) ist ein potenter, selektiver, gut vertrÄglicher peptidischer CXCR4-Antagonist mit einem IC50 < 10 nM. Balixafortide TFA zeigt eine 1000-fach hÖhere SelektivitÄt fÜr CXCR4 als eine große Gruppe von Rezeptoren, einschließlich CXCR7. Balixafortide TFA blockiert die β-Arrestin-Rekrutierung und den Kalziumfluss mit IC50s < 10 nM. Balixafortide TFA ist auch ein wirksames Mobilisierungsmittel fÜr hÄmatopoetische Stamm- und VorlÄuferzellen (HSPC). Anti-Krebs-Effekte.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2].
[1]. Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103. [2]. Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *